Author: Ken Dropiewski

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Research collaboration to target severe form of genetic dilated cardiomyopathy Collaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac therapy Collaboration allows Phlox Therapeutics to leverage Solid Biosciences’ vector biology and manufacturing capacities to deliver its RNA therapies to the heart CHARLESTOWN, Mass. and NAARDEN, The Netherlands, Jan. […]

CardioSolution Announces New Regional Chief Medical Officers

These appointments will assist in providing underserved patients with critical cardiovascular care across the nation. CINCINNATI–(BUSINESS WIRE)–CardioSolution, a leading comprehensive cardiovascular service line provider, recently announced two new appointments to its Regional Chief Medical Officers (RCMO) team of board-certified interventional cardiologists. As the newest members of the RCMO team, Alan Berger, […]

NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)

− Proprietary electron accelerator technology achieves “two beams on target” milestone, validating proof of concept for large-scale U.S. Mo-99 production without the use of uranium – − NorthStar has provided the only commercial, domestic U.S. supply of Mo-99 for more than four years; electron accelerator technology will increase production capability […]

EUROPEAN ASSOCIATION OF CARDIOVASCULAR IMAGING (EACVI) COLLABORATES WITH SURGICAL SCIENCE TO PILOT THE FIRST ONLINE TRANSESOPHAGEL ECHO (TOE) TESTING

ANTIBE, France, Jan. 10, 2023 /PRNewswire/ — The EACVI and Surgical Science have joined forces to create a unique TOE online simulator, aiming to evaluate TOE knowledge and performance level among young cardiologists and assess the need for simulation training for this purpose. The study, which included over 716 cardiologists from 81 countries tested […]

PENUMBRA LAUNCHES LATEST INNOVATION IN MECHANICAL THROMBECTOMY: LIGHTNING FLASH™

Lightning Flash™ is the most advanced mechanical thrombectomy system on the market to address venous and pulmonary thrombus Next generation technology combines superior catheter design with the latest dual clot detection innovation ALAMEDA, Calif., Jan. 10, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, announced the U.S. Food […]

Instylla Announces Enrollment of Initial Patient in the Prospective Multicenter “HALT” Study

Pivotal study to evaluate Embrace™ Hydrogel Embolic System for the embolization of arterial bleeds in the peripheral vasculature BEDFORD, Mass., Jan. 10, 2023 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment of the first patient in the HALT Study1 for the treatment of peripheral […]

GE HealthCare Announces Agreement to Acquire IMACTIS to Strengthen Capabilities in Interventional Guidance

Acquisition expected to provide significant future expansion opportunity for the IMACTIS CT-Navigation system through GE HealthCare’s large installed base and global scale IMACTIS CT-Navigation enables intuitive pre-planning, continuous control, and navigation throughout a range of minimally invasive percutaneous procedures This acquisition is the latest example demonstrating that GE HealthCare is executing […]

BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP™ Technology

Westport, CT, Jan. 10, 2023 (GLOBE NEWSWIRE) — Leading Midwest healthcare system reports significant cost savings and noise reduction following evaluation of the PURE EP™ System Medical center signs agreement to acquire the Company’s digital signal processing technology for arrhythmia care BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced […]

MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval

GENEVA, Jan. 10, 2023 /PRNewswire/ — SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of coronary de novo lesions. This comes less than eight months after the company received its first IDE approval for SELUTION SLR in the treatment […]